---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-267331"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2021-09-08T23:59:59+00:00"
generated_at: "2026-06-29T05:05:11.221470+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Catalyst Biosciences appoints Jeanne Jew to Board of Directors, increasing board size to eight

## Summary
- Jeanne Y. Jew appointed as Class III director effective September 9, 2021, term expiring at 2024 annual meeting.
- Board increased from seven to eight members in connection with the appointment.
- Ms. Jew is Chief Business Officer of ALX Oncology since August 2020, with over 25 years of corporate development experience.
- She will receive standard non-employee director cash and equity compensation and enter an indemnification agreement.

## SEC filing metadata
- accession: 0001193125-21-267331
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2021-09-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000119312521267331/0001193125-21-267331-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000119312521267331/d228933d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-267331
- JSON: https://secwatch.observer/filing/0001193125-21-267331.json
- Plain text: https://secwatch.observer/filing/0001193125-21-267331.txt

## Key facts
- Executive change
  Jeanne Y. Jew was appointed as Class III director at GYRE THERAPEUTICS, INC..
  - Action: appointed
  - Role: Class III director
  source text: On September 8, 2021, Catalyst Biosciences, Inc. (“Catalyst”) announced that the Board of Directors of Catalyst (the “Board”), has appointed, effective as of September 9, 2021 (the “Effective Date”), Ms. Jeanne Y. Jew as a Class III director of Catalyst with a term to expire at the 2024 Annual Meeting of Stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000119312521267331/0001193125-21-267331-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.